Nihon Kohden Corporation (NHNKY) Fair Value & Analysis
Healthcare · US · Market cap $1.5B
Nihon Kohden Corporation
NHNKY · US
Fair value as of: Aug 19, 2026
From 23 valuation models · updated yesterday
Share price −3.6% over the past month.
A solid business, screening 24% undervalued on our models.
What matters now
- A fairly wide model range ($7.77 to $15.67) leaves room in how you read the outcome.
- Our model range runs from $7.77 (bear) to $15.67 (bull), base $11.44. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 70/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range $8.25 – $19.18 · fair‑value band $7.77 – $15.67 · the $9.23 price screens below the $11.44 fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Nihon Kohden Corporation (NHNKY) currently trades at $9.23, while our model-based Fair Value estimate is $11.44, implying the stock looks roughly 23.9% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Nihon Kohden Corporation generated revenue of $232B at a net margin of 5.9%. Revenue declined 5.2% year over year. It earns a return on equity of 7.7%. The balance sheet holds a net cash position of ¥10.5B. Fundamentals as of Aug 19, 2026
Our scenario range runs from $7.77 (bear case) to $15.67 (bull case); at $9.23, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at 24%, NHNKY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings ($11.99) versus Asset-Based ($5.16). Highest evidence: Growth DCF (80).
Notify me when NHNKY reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Nihon Kohden Corporation engages in research and development, production, sales, and repair and maintenance of medical electronic equipment in Japan, North America, Latin America, Europe, Asia, and internationally.
Full company description
Nihon Kohden Corporation engages in research and development, production, sales, and repair and maintenance of medical electronic equipment in Japan, North America, Latin America, Europe, Asia, and internationally. It offers physiological measuring equipment, such as electroencephalographs, evoked potential and electromyogram measuring systems, electrocardiographs, polygraphs for Cath lab, diagnostic information systems, recording paper, electrodes, and EP catheters. The company also provides patient monitors such as central monitors, bedside monitors, wireless monitors, remote access software and other equipment, clinical information systems, and electrodes and sensors. In addition, it offers Defibrillators, AEDs, ventilators, pacemakers, anesthesia machines, cochlear implants, automated chest compression devices, AED pads, batteries, and ablation catheters; hematology analyzers, clinical chemistry analyzers, ultrasound diagnostic equipment and others, consumables, including test reagents, and installation and maintenance services. Further, it is involved in insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Nihon Kohden Corporation reported revenue of ¥249B in FY2026 versus ¥205B in FY2022, a compound +5.0%/yr. Reported net income was ¥15.4B in FY2026, compounding −10.0%/yr from FY2022.
of which total revenue +3.9 pp · buybacks/dilution +0.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch NHNKY: get an alert when its fair value changes →
Peer Group
Medical Devices · 360 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 240.60 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
| CLASSYS Inc 214150 | 39,700 KRW | 20,415 KRW | -49% |
Compare Nihon Kohden Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nihon Kohden Corporation (NHNKY) overvalued or undervalued?
What is the fair value of NHNKY?
What is the quality score of NHNKY?
What is the revenue of Nihon Kohden Corporation (NHNKY)?
What is the net profit margin of NHNKY?
Does Nihon Kohden Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Nihon Kohden Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.